Singapore markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
14.87+0.14 (+0.95%)
At close: 04:00PM EST
14.63 -0.24 (-1.61%)
Pre-market: 08:50AM EST
Full screen
Trade prices are not sourced from all markets
Previous close14.73
Open14.84
Bid0.00 x 1300
Ask0.00 x 1100
Day's range14.76 - 14.93
52-week range12.28 - 15.36
Volume2,225,873
Avg. volume3,078,316
Market cap46.232B
Beta (5Y monthly)0.75
PE ratio (TTM)30.35
EPS (TTM)0.49
Earnings dateN/A
Forward dividend & yield0.73 (5.00%)
Ex-dividend date30 Mar 2022
1y target est17.77
  • Business Wire

    Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

    OSAKA, Japan and CAMBRIDGE, Massachusetts, November 22, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of the Biologics License Application (BLA) for TAK-003, the company’s investigational dengue vaccine candidate. In the U.S., TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age.

  • Motley Fool

    Why Puma Biotechnology's Shares Jumped 20% on Monday

    The biopharmaceutical company specializes in cancer therapies. Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical trial as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence found in an abnormal chromosome 22, often seen in people with certain types of leukemia.

  • Business Wire

    Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US

    OSAKA, Japan & CAMBRIDGE, Mass, November 17, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treated with ICLUSIG® (ponatinib) plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease (MRD)-negative complete remission (CR) compared to imatinib. MRD-negativity is associated